Guardant Health
Blood test detecting cancer at Stage 1. FDA approval (January 2026) for Guardant360 CDx as companion diagnostic for BRAF V600E-mutant mCRC — regulatory milestone with direct revenue impact. MetaSight acquisition ($59M) extends liquid biopsy portfolio. 28 abstracts + 3 oral sessions at AACR 2026 validating pan-cancer monitoring (18 months earlier detection). 2026 screening revenue guidance $162-174M (210K-225K Shield tests, 2.5x growth from 87K in 2025).
Scenarios
10% penetration of colorectal screening-eligible population generates $2B+ annual revenue from single test. MetaSight adds liver fibrosis. Network effects compound as AI learning engine improves sensitivity with every patient.
Exact Sciences (Cologuard) owns significant mindshare. Insurance coverage battles are brutal and slow. Manufacturing quality at volume is operationally complex.
Key Factors to Watch
- ●FDA approval (January 2026) for Guardant360 CDx as BRAF V600E companion diagnostic — direct revenue milestone
- ●Shield test — 210K-225K projected 2026 (2.5x growth from 87K in 2025), $162-174M screening revenue guidance
- ●MetaSight acquisition ($59M) adds liver fibrosis detection — second major TAM
- ●AI learning engine improves sensitivity with every patient — compounding moat
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-04-10 | 8.0 | Very Positive | Score 7.8→8.0 (are 8→9). FDA approval (Jan 2026) for Guardant360 CDx BRAF companion diagnostic + MetaSight acquisition + 28 AACR abstracts + $162-174M screening revenue guidance. Direction positive → very_positive. |
| 2026-03-08 | 7.8 | Positive | Score 7.6→7.8 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.6 | Positive | Initial assessment from batch 8 research |
Healthcare Peers
Last researched: 2026-03-17
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.